AstraZeneca bets $2B on Jacobio’s pan-KRAS cancer drug
Jacobio Pharma granted AstraZeneca exclusive global development and commercialization rights to its experimental pan-KRAS inhibitor JAB-23E73 in a licensing agreement announced December 21 with a pote...